1. Home
  2. VMO vs MNPR Comparison

VMO vs MNPR Comparison

Compare VMO & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VMO

Invesco Municipal Opportunity Trust

N/A

Current Price

$8.39

Market Cap

642.0M

Sector

Finance

ML Signal

N/A

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

N/A

Current Price

$69.15

Market Cap

587.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VMO
MNPR
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
642.0M
587.4M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
VMO
MNPR
Price
$8.39
$69.15
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $130.17
AVG Volume (30 Days)
★ 232.1K
123.7K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.99
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.12
$50.07
52 Week High
$10.10
$124.82

Technical Indicators

Market Signals
Indicator
VMO
MNPR
Relative Strength Index (RSI) 31.56 40.33
Support Level $8.12 $66.88
Resistance Level $9.84 $75.33
Average True Range (ATR) 0.14 4.72
MACD -0.07 0.64
Stochastic Oscillator 7.74 38.08

Price Performance

Historical Comparison
VMO
MNPR

About VMO Invesco Municipal Opportunity Trust

Invesco Municipal Opportunity Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: